Wang et al. have found that CTD and NCTD might enhance the toxicity of gemcitabine and erlotinib for human pancreatic cancer cells by inhibiting the beta-catenin pathway, thus augmenting treatment of pancreatic cancer (Wang W. J. et al., 2015). Here, CTNNB1 is linked to familial pancreatic carcinoma.